Dyne Therapeutics Inc (DYN) Stock Price, Quote & News

Company Profile

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therap...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 786 8230

Fax: 781 786 8866

Website: www.dyne-tx.com

Address:

1560 Trapelo Road, Waltham, United States

Iightning Nov. 19 at 11:51 PM

1ightning® Options Trade Alert (Actionable) | Buy $DYN Dec 19 $21 Call | Enter: $2.08 Exit: $3.75 | Profit: 80.94% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 19 at 8:07 AM

1ightning® Options Trade Alert (Actionable) | Buy $DYN Dec 19 $21 Call | Enter: $2.08 Exit: $3.75 | Profit: 80.94% ROI | https://1ightning.com

0 · Reply

JarvisFlow Nov. 14 at 3:52 PM

JP Morgan has adjusted their stance on Dyne Therapeutics ( $DYN ), setting the rating to Neutral with a target price of 18 → 17.

0 · Reply

JarvisFlow Nov. 12 at 4:16 PM

Oppenheimer updates rating for Dyne Therapeutics ( $DYN ) to Perform, target set at 13 → 11.

0 · Reply

stockwitsuser2449 Nov. 7 at 12:29 PM

$QURE $BIOA $DYN and $NPCE now. glta

0 · Reply

JarvisFlow Nov. 6 at 4:37 PM

HC Wainwright & Co. has adjusted their stance on Dyne Therapeutics ( $DYN ), setting the rating to Buy with a target price of 38 → 46.

0 · Reply

JarvisFlow Nov. 6 at 3:52 PM

RBC Capital updates rating for Dyne Therapeutics ( $DYN ) to Outperform, target set at 23 → 30.

0 · Reply

_www_larval_com_ Nov. 6 at 2:42 PM

$FTEL -13%[26%] $ACVA -10%[-38%] $GDTC -10%[2%] $DYN -8%[-13%] $CTKB 6%[18%] most notable movement within the first minutes of trading.

0 · Reply

RNASequencing Nov. 5 at 9:48 PM

$DYN uhhh huge delay via enrollment problems for registrational study. Often a leading indicator for investigator enthusiasm for the drug. Don’t want to short the hole but this should be down more

0 · Reply

stockwitsuser2449 Nov. 5 at 9:24 PM

$DYN going back to 14 or lower IMO

0 · Reply

Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 3, 2025, 7:30 AM EST - 16 days ago

Dyne Therapeutics to Present at Upcoming Investor Conferences

Oct 27, 2025, 4:54 PM EDT - 23 days ago

This biotech's stock soared as investors look for the next buyout target

Oct 8, 2025, 4:42 PM EDT - 6 weeks ago

Dyne: Accelerated Approval Established Endpoint Sets Stage For DM1 Data In Mid-2026

Oct 6, 2025, 6:01 PM EDT - 6 weeks ago

Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)

Oct 2, 2025, 4:05 PM EDT - 6 weeks ago

Dyne Therapeutics Appoints Brian Posner to its Board of Directors

Sep 29, 2025, 8:35 AM EDT - 7 weeks ago

Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy

Sep 8, 2025, 12:24 PM EDT - 2 months ago

Dyne Therapeutics, Inc. (DYN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Aug 4, 2025, 7:30 AM EDT - 3 months ago

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD)

Jul 29, 2025, 12:51 PM EDT - 4 months ago

These Analysts Lower Their Forecasts On Dyne Therapeutics Following Q2 Loss

Jul 28, 2025, 4:10 PM EDT - 4 months ago

Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Jul 16, 2025, 7:00 AM EDT - 4 months ago

Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer

Jul 2, 2025, 4:01 PM EDT - 5 months ago

Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Jul 1, 2025, 9:00 AM EDT - 5 months ago

Tesla, Progress Software, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

PRGS TSLA

Jun 30, 2025, 9:45 PM EDT - 5 months ago

Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock

Jun 30, 2025, 4:05 PM EDT - 5 months ago

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

Jun 30, 2025, 4:01 PM EDT - 5 months ago

Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital

Jun 24, 2025, 3:43 AM EDT - 5 months ago

Dyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - DYN

Jun 18, 2025, 11:08 AM EDT - 5 months ago

Dyne Therapeutics - Emergence As A Superior DM1 / DMD Player Warrants Rating Upgrade

Jun 17, 2025, 1:35 PM EDT - 5 months ago

Dyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – DYN

Jun 17, 2025, 7:00 AM EDT - 5 months ago

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting

Jun 16, 2025, 4:05 PM EDT - 5 months ago

Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET

Jun 5, 2025, 7:30 AM EDT - 5 months ago

Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress

May 8, 2025, 7:30 AM EDT - 6 months ago

Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Apr 24, 2025, 7:30 AM EDT - 7 months ago

Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy

Apr 15, 2025, 7:30 AM EDT - 7 months ago

Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments

Apr 14, 2025, 4:30 PM EDT - 7 months ago

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 20, 2025, 4:30 PM EDT - 8 months ago

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer

Mar 20, 2025, 4:10 PM EDT - 8 months ago

Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer

Mar 16, 2025, 7:00 PM EDT - 8 months ago

Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months

Mar 13, 2025, 9:09 AM EDT - 8 months ago

Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate Biomarker

Mar 12, 2025, 3:05 PM EDT - 9 months ago

Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks

Mar 11, 2025, 7:30 AM EDT - 9 months ago

Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum

Feb 27, 2025, 7:30 AM EST - 9 months ago

Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Feb 14, 2025, 4:05 PM EST - 9 months ago

Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference

Feb 3, 2025, 7:30 AM EST - 10 months ago

Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 21, 2025, 7:30 AM EST - 10 months ago

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Jan 10, 2025, 1:40 PM EST - 11 months ago

Why Is Neuromuscular-Focused Dyne Therapeutics Stock Trading Lower On Friday?

Jan 10, 2025, 6:30 AM EST - 11 months ago

Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026

Jan 9, 2025, 7:30 AM EST - 11 months ago

Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Jan 8, 2025, 4:05 PM EST - 11 months ago

Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET

Nov 11, 2024, 6:15 PM EST - 1 year ago

Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases

Nov 3, 2024, 11:00 AM EST - 1 year ago

Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm

Oct 31, 2024, 11:00 AM EDT - 1 year ago

Dyne Therapeutics Inc Is Being Sued For Securities Fraud And Shareholders With Losses Are Urged To Contact The Schall Law Firm

Iightning Nov. 19 at 11:51 PM

1ightning® Options Trade Alert (Actionable) | Buy $DYN Dec 19 $21 Call | Enter: $2.08 Exit: $3.75 | Profit: 80.94% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 19 at 8:07 AM

1ightning® Options Trade Alert (Actionable) | Buy $DYN Dec 19 $21 Call | Enter: $2.08 Exit: $3.75 | Profit: 80.94% ROI | https://1ightning.com

0 · Reply

JarvisFlow Nov. 14 at 3:52 PM

JP Morgan has adjusted their stance on Dyne Therapeutics ( $DYN ), setting the rating to Neutral with a target price of 18 → 17.

0 · Reply

JarvisFlow Nov. 12 at 4:16 PM

Oppenheimer updates rating for Dyne Therapeutics ( $DYN ) to Perform, target set at 13 → 11.

0 · Reply

stockwitsuser2449 Nov. 7 at 12:29 PM

$QURE $BIOA $DYN and $NPCE now. glta

0 · Reply

JarvisFlow Nov. 6 at 4:37 PM

HC Wainwright & Co. has adjusted their stance on Dyne Therapeutics ( $DYN ), setting the rating to Buy with a target price of 38 → 46.

0 · Reply

JarvisFlow Nov. 6 at 3:52 PM

RBC Capital updates rating for Dyne Therapeutics ( $DYN ) to Outperform, target set at 23 → 30.

0 · Reply

_www_larval_com_ Nov. 6 at 2:42 PM

$FTEL -13%[26%] $ACVA -10%[-38%] $GDTC -10%[2%] $DYN -8%[-13%] $CTKB 6%[18%] most notable movement within the first minutes of trading.

0 · Reply

RNASequencing Nov. 5 at 9:48 PM

$DYN uhhh huge delay via enrollment problems for registrational study. Often a leading indicator for investigator enthusiasm for the drug. Don’t want to short the hole but this should be down more

0 · Reply

stockwitsuser2449 Nov. 5 at 9:24 PM

$DYN going back to 14 or lower IMO

0 · Reply

stockwitsuser2449 Nov. 5 at 9:16 PM

$DYN “We continue to advance z-basivarsen toward a U.S. Accelerated Approval submission in DM1 and now anticipate full enrollment in the ongoing Registrational Expansion Cohort of our ACHIEVE trial in early Q2 2026. This is a change from previous guidance of Q4 2025,

0 · Reply

stockwitsuser2449 Nov. 5 at 9:14 PM

$DYN Research and development (R&D) expenses: R&D expenses were $97.2 million for the three months ended September 30, 2025 compared to $92.8 million for the three months ended September 30, 2024 . General and administrative (G&A) expenses: G&A expenses were $16.7 million for the three months ended September 30, 2025 compared to $12.9 million for the three months ended September 30, 2024 .

0 · Reply

stockwitsuser2449 Nov. 5 at 9:13 PM

$DYN earning out Net loss: Net loss for the three months ended September 30, 2025 was $108.0 million , or $0.76 per basic and diluted share. This compares with a net loss of $97.1 million , or $0.96 per basic and diluted share, for the three months ended September 30, 2024 .

0 · Reply

stockwitsuser2449 Nov. 5 at 6:21 PM

$DYN

0 · Reply

tedevan Nov. 4 at 9:31 PM

$DYN $RNA $SRPT $ARWR

1 · Reply

stockwitsuser2449 Nov. 4 at 5:57 PM

$DYN looking for 20 for the options play

0 · Reply

paid2win Nov. 4 at 1:56 AM

$DYN Dyne Therapeutics' stock is dropping due to several factors, including a recent analyst downgrade from Oppenheimer and a lowered price target from JPMorgan Chase, which shifted analyst sentiment. Other factors include a "surprise" pivot in its trial endpoint for myotonic dystrophy type 1 (DM1) and some insider stock selling. Analyst sentiment Downgrade: Oppenheimer downgraded the stock from "outperform" to "market perform," which contributed to the stock's drop. Price target reduction: JPMorgan Chase lowered its price target for the stock. Diverging ratings: Several different rating changes from multiple firms have impacted sentiment around the stock. Clinical trial and regulatory changes Endpoint shift: Dyne announced a change to the primary endpoint of its Phase 2 trial for its DM1 drug, DYNE-101. It will now use video hand opening time (vHOT) to measure myotonia, a change that reportedly surprised investors and caused the stock to drop. FDA agreement:

0 · Reply

RunnerSignals Nov. 3 at 9:11 PM

Market Warriors Flip the Script $GSIT $BFLY $CTMX $BW $DYN started down but came back swinging

0 · Reply

stockwitsuser2449 Nov. 3 at 6:14 PM

$QURE just need my $BIOA and $DYN puts to pay this big

0 · Reply

stockwitsuser2449 Nov. 1 at 6:33 PM

$DYN just options on this one

0 · Reply

cranio_verde Oct. 31 at 6:07 PM

$DYN

0 · Reply

stockwitsuser2449 Oct. 28 at 6:06 PM

$LUNG whats a better short this or $BIOA ...don't hate just wondering opinions of shorts (also $DYN why not ...)

1 · Reply

Market Cap	2.99B
Revenue (ttm)	0.00
Net Income (ttm)	-317.42M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.14

Volume	1,991,300
Avg Vol	2,718,718
Day's Range	N/A - N/A
Shares Out	142.83M
Stochastic %K	72%
Beta	1.16
Analysts	Strong Sell
Price Target	$35.70